Asthma – Global Drug Forecast and Market Analysis to 2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Asthma Market Report Overview
The Asthma market size across the 7MM was $9.7 billion in 2019 and is expected to achieve a CAGR of more than 1% during 2019-2029. Asthma is a common chronic lung disease characterized by chronic inflammation and subsequent narrowing of the airways, that most often develops during childhood, but can occur at any age. Asthma can be persistent or intermittent and varies by severity. The symptoms of asthma are often triggered by factors such as exercise, allergen or irritant exposure, and even viral infections.
Asthma Market Outlook, 2019-2029 ($ Billion)
Buy Full Report to Gain More Information about the Asthma Market Forecast
The Asthma drug market research report provides an overview of the risk factors, comorbidities, and global and historical trends for Asthma in the seven major markets. It also discusses the factors driving the market, the challenges faced by it, and the key competitors within the market.
Market Size (2019) | $9.7 billion |
CAGR (2019 – 2029) | >1% |
Historical Period | 2019-2022 |
Forecast Period | 2023-2029 |
Key Class of Drugs | · Short-Acting Beta 2 Agonists (SABAs)
· Inhaled Corticosteroids (ICS) · ICS/LABA Fixed Dose Combinations · Leukotriene Inhibitors · Long-Acting Muscarinic Antagonists (LAMAs) · ICS/LABA/LAMA Fixed Dose Combinations · Monoclonal antibodies · Prostaglandin D2 Receptor 2 · ICS/SABA |
Leading Players | · AstraZeneca
· Novartis · Roche/Genentech · GlaxoSmithKline · Teva · Boehringer Ingelheim · Merck · Chiesi · Regeneron/Sanofi · AB Science SA |
Enquiry & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Asthma Market Drivers
The major driver in the Asthma market across the 7MM is the uptake of targeted biologic agents and the use of ICS/LABA and ICS/SABA for rescue therapy. Additionally, the entry of ICS/LABA/LAMA FDCs is expected to improve compliance and thus may have an overall positive impact on sales. Strong brand loyalty will result in difficulty replacing inhaler devices thus, softening the impact of generic erosion.
Asthma Market Segmentation by Class of Drugs
The key classes of drugs in the US Asthma market are Short-Acting Beta 2 Agonists (SABAs), Inhaled Corticosteroids (ICS), ICS/LABA Fixed Dose Combinations, Leukotriene Inhibitors, Long-Acting Muscarinic Antagonists (LAMAs), ICS/LABA/LAMA Fixed Dose Combinations, Monoclonal antibodies, Prostaglandin D2 Receptor 2, and ICS/SABA. In 2019, the leading drug class in the US Asthma market was Monoclonal antibodies.
Asthma Market Analysis by Class of Drugs in the US, 2019 (%)
Buy Full Report for More Asthma Classes of Drugs Insights
Asthma Market - Competitive Landscape
Some of the leading players in the Asthma market are AstraZeneca, Novartis, Roche/Genentech, GlaxoSmithKline, Teva, Boehringer Ingelheim, Merck, Chiesi, Regeneron/Sanofi, and AB Science SA. GSK was the leading player in 2019 followed by AstraZeneca. Both have a variety of successfully marketed products. However, GSK strategically introduced its inhalers to revitalize its respiratory drug portfolio in the face of generic erosion. Since then, GSK’s respiratory portfolio has expanded.
Asthma Market Analysis by Players, 2019 (%)
Buy Full Report for More Asthma Player Insights
Segments Covered in the Report
Asthma Class of Drugs Outlook (Value, $ Billion, 2019-2029)
- Short-Acting Beta 2 Agonists (SABAs)
- Inhaled Corticosteroids (ICS)
- ICS/LABA Fixed Dose Combinations
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMAs)
- ICS/LABA/LAMA Fixed Dose Combinations
- Monoclonal antibodies
- Prostaglandin D2 Receptor 2
- ICS/SABA
Scope
This report provides:
- Overview of asthma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline asthma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting asthma therapeutics sales in the 7MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global asthma therapeutics market.
- Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
- The greatest drivers of growth in the global asthma market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
- The main barriers to growth in the asthma market include high genericization of historical drug classes.
- Late-stage pipeline products in the ICS/LABA/LAMA triple-therapy fixed dose inhalers, CRTH2 antagonists, and ICS/SABA double therapies are emerging as distinct drug classes in the field.
- The most important unmet needs in the asthma market are improved drug compliance and personalized therapy for the most severe patients.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the global asthma therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Novartis
Roche/Genentech
GlaxoSmithKline
Teva
Boehringer Ingelheim
Merck
Chiesi
Regeneron/Sanofi
AB Science SA
Table of Contents
Table
Figures
Frequently asked questions
-
What was the Asthma market size in 2019?
The Asthma market size was $9.7 billion in 2019.
-
What is the Asthma market growth rate?
The Asthma market is expected to achieve a CAGR of more than 1% during 2019-2029.
-
Which was the leading drug class in the US Asthma market in 2019?
In 2019, the leading drug class in the US Asthma market was Monoclonal antibodies.
-
Who were the leading players in the Asthma market?
Some of the leading players in the Asthma market were AstraZeneca, Novartis, Roche/Genentech, GlaxoSmithKline, Teva, Boehringer Ingelheim, Merck, Chiesi, Regeneron/Sanofi, and AB Science SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.